rawfin.tv
Cue Biopharma Appoints CFO, Submits IND for CUE-221
Top StoriesstocksAI Generated

Cue Biopharma Appoints CFO, Submits IND for CUE-221

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Cue Biopharma announced the appointment of James M. Ahlers as its new Chief Financial Officer. The company also submitted an Investigational New Drug (IND) application for its CUE-221 candidate, marking a significant step in its drug development pipeline.

BiotechnologyDrug DevelopmentCorporate GovernanceCUE

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks